Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Pharmacoeconomics
|
October 11, 2016
Modeling Treatment Sequences in Pharmacoeconomic Models
Ying Zheng, Feng Pan, Sonja Sorensen
Pharmacoeconomics - Open
|
January 9, 2019
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Peter L Quon, Ying Xiao, Sonja Sorensen, et al.
Applied Health Economics and Health Policy
|
October 4, 2012
Inclusion of compliance and persistence in economic models: past, present and future
Ananth Kadambi, Robert J Leipold, Anuraag R Kansal, et al.
Pharmacoeconomics
|
April 9, 2017
Comment on: "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal"
Odette Reifsnider, Fiona Hall, Sonja Sorensen, et al.
Journal of the International AIDS Society
|
November 14, 2014
Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
Siyang Peng, Ali Tafazzoli, Emily Dorman, et al.
Journal of Managed Care Pharmacy : JMCP
|
October 26, 2013
Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer
Sonja Sorensen, Lorie Ellis, Ying Wu, et al.
Journal of Medical Economics
|
May 3, 2015
Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
Siyang Peng, Ali Tafazzoli, Emily Dorman, et al.
Breast Cancer Research and Treatment
|
January 25, 2007
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial
Gershon Y Locker, Robert Mansel, David Cella, et al.
Journal of Evaluation in Clinical Practice
|
June 16, 2010
Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis
Roger S McIntyre, Lael Cragin, Sonja Sorensen, et al.
Clinical Therapeutics
|
January 8, 2017
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
Sonja Sorensen, Mark Wildgust, Nishan Sengupta, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Pharmacoeconomics
|
October 11, 2016
Modeling Treatment Sequences in Pharmacoeconomic Models
Ying Zheng, Feng Pan, Sonja Sorensen
Pharmacoeconomics - Open
|
January 9, 2019
Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
Peter L Quon, Ying Xiao, Sonja Sorensen, et al.
Applied Health Economics and Health Policy
|
October 4, 2012
Inclusion of compliance and persistence in economic models: past, present and future
Ananth Kadambi, Robert J Leipold, Anuraag R Kansal, et al.
Pharmacoeconomics
|
April 9, 2017
Comment on: "Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal"
Odette Reifsnider, Fiona Hall, Sonja Sorensen, et al.
Journal of the International AIDS Society
|
November 14, 2014
Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
Siyang Peng, Ali Tafazzoli, Emily Dorman, et al.
Journal of Managed Care Pharmacy : JMCP
|
October 26, 2013
Budgetary impact on a U.S. health plan adopting abiraterone acetate plus prednisone for the treatment of patients with metastatic castration-resistant prostate cancer
Sonja Sorensen, Lorie Ellis, Ying Wu, et al.
Journal of Medical Economics
|
May 3, 2015
Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States
Siyang Peng, Ali Tafazzoli, Emily Dorman, et al.
Breast Cancer Research and Treatment
|
January 25, 2007
Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial
Gershon Y Locker, Robert Mansel, David Cella, et al.
Journal of Evaluation in Clinical Practice
|
June 16, 2010
Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis
Roger S McIntyre, Lael Cragin, Sonja Sorensen, et al.
Clinical Therapeutics
|
January 8, 2017
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
Sonja Sorensen, Mark Wildgust, Nishan Sengupta, et al.
Page
of 2